Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. The CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of precise, high dose radiation while patients breathe normally. It also offers the TomoTherapy System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. The company markets its products in the United States directly, as well as through a sales agent and group purchasing organizations; and directly and through distributors and sales agents in Europe, Japan and other countries of Asia, South America, and internationally to hospitals and stand-alone treatment facilities. Accuray Incorporated was incorporated in 1990 and is headquartered in Sunnyvale, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:ARAY
CUSIP00439710
Phone408-716-4600
Debt
Debt-to-Equity Ratio3.00
Current Ratio1.62
Quick Ratio0.97
Price-To-Earnings
Trailing P/E Ratio-10.83
Forward P/E Ratio-13.10
P/E GrowthN/A
Sales & Book Value
Annual Sales$383.41 million
Price / Sales0.85
Cash FlowN/A
Price / CashN/A
Book Value$0.56 per share
Price / Book6.79
Profitability
EPS (Most Recent Fiscal Year)($0.36)
Net Income$-29,570,000.00
Net Margins-7.00%
Return on Equity-52.91%
Return on Assets-6.25%
Miscellaneous
Employees944
Outstanding Shares85,640,000
Market Cap$333.99
Accuray (NASDAQ:ARAY) Frequently Asked Questions
What is Accuray's stock symbol?
Accuray trades on the NASDAQ under the ticker symbol "ARAY."
How were Accuray's earnings last quarter?
Accuray Incorporated (NASDAQ:ARAY) released its quarterly earnings data on Monday, April, 30th. The medical equipment provider reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by $0.05. The medical equipment provider had revenue of $99.83 million for the quarter, compared to analyst estimates of $98.18 million. Accuray had a negative net margin of 7.00% and a negative return on equity of 52.91%. View Accuray's Earnings History.
When is Accuray's next earnings date?
What price target have analysts set for ARAY?
6 brokerages have issued 1 year price objectives for Accuray's stock. Their predictions range from $6.00 to $10.00. On average, they expect Accuray's share price to reach $7.40 in the next year. This suggests a possible upside of 94.7% from the stock's current price. View Analyst Ratings for Accuray.
What is the consensus analysts' recommendation for Accuray?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accuray in the last year. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
Who are some of Accuray's key competitors?
Some companies that are related to Accuray include Tandem Diabetes Care (TNDM), Cardiovascular Systems (CSII), Atrion (ATRI), Orthofix International (OFIX), Cryolife (CRY), OraSure Technologies (OSUR), Intersect ENT (XENT), AtriCure (ATRC), K2M Group (KTWO), Tactile Systems Technology (TCMD), Cerus (CERS), SurModics (SRDX), AngioDynamics (ANGO), LeMaitre Vascular (LMAT) and Anika Therapeutics (ANIK).
Who are Accuray's key executives?
Accuray's management team includes the folowing people:
- Mr. Joshua H. Levine, Pres, Chief Exec. Officer & Director (Age 60)
- Mr. Kevin Waters, Sr. VP & CFO (Age 41)
- Mr. Andrew Kirkpatrick, Sr. VP of Global Operations (Age 55)
- Ms. Alaleh Nouri, Sr. VP, Gen. Counsel & Corp. Sec. (Age 39)
- Mr. Lionel Hadjadjeba, Sr. VP & Chief Commercial Officer (Age 59)
Has Accuray been receiving favorable news coverage?
Press coverage about ARAY stock has trended somewhat positive on Monday, Accern reports. Accern identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Accuray earned a news sentiment score of 0.16 on Accern's scale. They also assigned news stories about the medical equipment provider an impact score of 46.21 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
How do I buy shares of Accuray?
Shares of ARAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Accuray's stock price today?
One share of ARAY stock can currently be purchased for approximately $3.80.
How big of a company is Accuray?
Accuray has a market capitalization of $333.99 million and generates $383.41 million in revenue each year. The medical equipment provider earns $-29,570,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Accuray employs 944 workers across the globe.
How can I contact Accuray?
Accuray's mailing address is 1310 CHESAPEAKE TERRACE, SUNNYVALE CA, 94089. The medical equipment provider can be reached via phone at 408-716-4600 or via email at [email protected]
MarketBeat Community Rating for Accuray (NASDAQ ARAY)
MarketBeat's community ratings are surveys of what our community members think about Accuray and other stocks. Vote "Outperform" if you believe ARAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARAY will underperform the S&P 500 over the long term. You may vote once every thirty days.
